- Insulet reported the results from the first pivotal trial of Omnipod 5 System in patients with T1D. The trial enrolls two groups that include 28 adults & adolescents aged 14-70yrs. and 112 children aged 6-13.9yrs.
- Results: In adults & adolescents and children, increase in time in range (70-180mg/dL) from 65% to 74% (additional 2.2hr/day) and 53% to 68% (additional 3.7hrs/day) with reduction of HbA1c from (7.16% to 6.78% and 7.67% to 6.99%), decrease in mean glucose (161 to 154 mg/dL and 183 to 160 mg/dL) respectively
- The Omnipod 5 System received FDA’s BTD and is currently under review. Insulet is expected to launch Omnipod 5 in limited release in H1’21
Click here to read full press release/ article | Ref: Insulet | Image: National Investor Network